Stocks · News reference
XORTX Outlines Anticipated FDA IND Submission For XRx-026 Gout Program
XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
XORTX Therapeutics (XRTX) Stock Climbs 16% After Hours: Here's What You Need to Know
XORTX Therapeutics shares rose 16.11% after hours after the biotech announced a key manufacturing milestone for its lead gout program.